Therapies adjusted to achieve a BNP (target value<100 ng/L) resulted in more frequent changes 134 versus 66 in clinical group (p < 0.05); with all types of HF drugs changed more frequently in the BNP group. This evidence concerns the gene NPPB and hydrops fetalis.